Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 1.00 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011347 | 1.00 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14IRAK4 | |
| SCHEMBL2009749 | 0.91 | TGFBR1 (1.00) | TGFBR1TGFB2IRAK4 | |
| SCHEMBL29978376 | 0.91 | TGFBR1 (1.00) | TGFBR1TGFB2IRAK4 | |
| SCHEMBL2012220 | 0.87 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL31498979 | 0.87 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2007716 | 0.83 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL31498978 | 0.82 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2008286 | 0.82 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2011307 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL31498977 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352530-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | MANNKIND CORP (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4333853-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | Thirona Bio, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117615765-A | Methods of treating pulmonary diseases with ALK-5 (TGF beta R1) inhibitors | 蒂罗纳生物股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2022235621-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | THIRONA BIO, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352530-A1 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | KIT, MAP3K15, PRKCZ | TGFBR1 806/4885TGFB2 766/4885MAPK14 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.